HER2-positive Gastric Cancer Clinical Trial
Official title:
Predictive Biomarkers Screening by ctDNA Detection in Advanced HER2 Positive Gastric Cancer Patients Treated by Trastuzumab Plus Chemotherapy
To identify molecular biomarker panel correlating with efficacy of trastuzuamb in advanced HER2 positive gastric cancer patients. To observe the molecular evolution of HER2 positive gastric cancer during treatment by ctDNA detection.
Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05070598 -
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT03330561 -
PRS-343 in HER2-Positive Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05619016 -
[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT05586061 -
First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT05190445 -
Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
|
Phase 2 | |
| Recruiting |
NCT05982834 -
Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05313906 -
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT06328738 -
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04319757 -
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06253650 -
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
|
Phase 2 | |
| Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
| Not yet recruiting |
NCT06414733 -
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05555251 -
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06439550 -
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
|
Phase 2 | |
| Recruiting |
NCT05514717 -
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
|
Phase 1 | |
| Terminated |
NCT05091528 -
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 |